Actively Recruiting
Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration
Led by Kissei Pharmaceutical Co., Ltd. · Updated on 2025-06-27
142
Participants Needed
1
Research Sites
91 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study to evaluate the efficacy and safety of KPS-0373 given once daily after breakfast in 142 patients with spinocerebellar degeneration . This study consists of the 4-week screening period, 24-week treatment period, and 4-week follow-up period.
CONDITIONS
Official Title
Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Japanese patients diagnosed with spinocerebellar degeneration
- Patients with mild to moderate ataxia
You will not qualify if you...
- Patients with secondary ataxia
- Patients with clinically significant liver, kidney, or heart problems
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Research Site
Multiple Locations, Japan
Actively Recruiting
Research Team
K
Kissei Pharmaceutical Co., Ltd Kissei Pharmaceutical Co., Ltd
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here